Drug intelligence / Profile preview

OvaStem

Development stage: Preclinical
Lead developer: Creative Medical Technology
Modality: Cell Therapies
Administration: Intraovarian

Overview

OvaStem is an autologous regenerative cell therapy developed by Creative Medical Technology for women with primary ovarian insufficiency. The procedure uses a patient's own bone marrow aspirate, which is collected and then administered directly into the ovaries through a minimally invasive outpatient approach intended to restore ovarian endocrine activity and improve fertility potential. Rather than acting through a single defined molecular target, the therapy is positioned as a personalized bone marrow aspirate based cell therapy designed to promote ovarian tissue repair and functional recovery, and it has been advanced by the company as an alternative to conventional fertility approaches such as in vitro fertilization in this setting.

Brand names: OvaStem
Other names: OvaStem

Beyond the preview

Go deeper on OvaStem.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OvaStem.

Explore the full profile